Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health Incorporated

Elanco provides products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. This is a self-described leading provider of innovative solutions in animal health.

msh id	COM:ELANCO
symbol	ELAN
name	Elanco Animal Health Incorporated
homepage url	https://www.elanco.com
country	US
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	9.3K
crunchbase url	-
linkedin url	-
founders	-

market cap	6.56B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.02
growth cost of revenue	0.01
growth depreciation and amortization	0.31
growth ebitda	0.07
growth ebitda ratio	0.07
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	-0.01
growth gross profit ratio	-0.01

COM:ELANCO

Elanco

Last Close

13.44

21/11 21:00

Market Cap

6.56B

Beta: -

Volume Today

4.56M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	4.09B
cost of revenue	4.09B
depreciation and amortization	694M
ebitda	945M
ebitda ratio	0.21
eps	-2.5
eps diluted	-2.5
operating expenses	2.16B
operating income	326M
operating income ratio	0.07

accounts receivables	-40M
capital expenditure	-154M
cash at beginning of period	345M
cash at end of period	352M
inventory	1.74B
working capital ttm	2.3B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-